Comparative Pharmacology
Head-to-head clinical analysis: BETAPACE versus KERLONE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BETAPACE versus KERLONE.
BETAPACE vs KERLONE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Class III antiarrhythmic agent; prolongs cardiac action potential duration and refractory period by blocking potassium channels, primarily IKr.
Selective beta-1 adrenergic receptor antagonist; reduces heart rate, myocardial contractility, and blood pressure.
Oral: 80 mg twice daily; may increase up to 160 mg twice daily as needed.
10 mg orally once daily; may increase to 20 mg once daily if needed. Maximum 20 mg/day.
None Documented
None Documented
12 hours (10-20 hours) in patients with normal renal function; prolonged in renal impairment, requiring dose adjustment
Terminal elimination half-life is 8-12 hours in healthy adults; may extend to 15-20 hours in renal impairment (CrCl <30 mL/min).
Renal: >90% unchanged drug (sotalol) in urine; biliary/fecal: <10%
Primarily renal excretion of unchanged drug and metabolites (70-80% unchanged; 20-30% as glucuronide or sulfate conjugates). Biliary/fecal excretion accounts for less than 5%.
Category C
Category C
Beta-Blocker
Beta-Blocker